Prevnar

Type: Product
Name: Prevnar
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Business Solutions Director, Business Analytics - Vaccines

Org Marketing StatementAll over the world, Pfizer colleagues are working together to positively impact health for everyone, everywhere. Each position at Pfizer touches and contributes to the success of our business and our world. That’s why, as one of ... [Published PharmaDiversity - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Vaccine costs soar

There is little that Dr. Lindsay Irvin has not done for the children's vaccines in her office refrigerator: She remortgaged her home to afford their rising prices. She packed them in ice chests and moved them when her office flooded this year. She pays ... [Published Tampa Bay Times - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Human medicines European public assessment report (EPAR): Prevenar, pneumococcal saccharide conjugated vaccine, adsorbed, Revision: 20, Authorised

Entities: Prevnar, Vaccine
First reported Jul 14 2014 - Updated Jul 15 2014 - 2 reports

Prices of vaccines–an uncomfortable discussion

Suddenly, there has been a lot of noise about the price of vaccines. Well, there's always been over-exaggerations and outright misinformation about vaccine prices and profits from the antivaccination gang, and they must be embarrassed by the quality of ... [Published Daily Kos - Jul 15 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Could soaring vaccine prices spark Sovaldi-style payer pushback?

With the expense of vaccine production often higher than the manufacturing costs for pharmaceuticals, vaccines once led losses for their manufacturers. But today, vaccines--like Pfizer's ($PFE) Prevnar 13, which scored more than $4 billion in worldwide ... [Published FierceVaccines - Jul 11 2014]
Entities: Vaccine, Prevnar, Pfizer Inc
First reported Jul 03 2014 - Updated Jul 04 2014 - 3 reports

Vaccine Refusal Myths Drive Up Development Costs, Prices

Since last June, Elisabeth Rosenthal at The New York Times has been putting together a deeply reported  investigative series on healthcare costs in the U.S. called “Paying Till It Hurts.” The primary theme of the series is to identify the key factors ... [Published Forbes.com - Jul 03 2014]
Entities: Vaccine, Prevnar, Immunity
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

How Vaccines Got Really Expensive

There is little that Dr. Lindsay Irvin has not done for the children’s vaccines in her office refrigerator: She remortgaged her home to afford their rising prices. She packed them in ice chests and moved them when her office flooded this year. She pays ... [Published Governing - Jul 03 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Prevnar use in seniors is cost-effective now, CDC says. But will it last?

After meeting to discuss the use of Pfizer's($PFE) Prevnar 13 in adults 65 and older late last week, a CDC advisory committee isn't planning to vote on recommendation of the shot just yet. But when it does, it will have a few things to consider--including ... [Published FierceVaccines - Jun 30 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

The top 5 vaccines by 2020

Pfizer's ( $PFE ) Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma . In fact, it's expected to widen its lead, with sales growing more ... [Published FierceVaccines - Jun 27 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Pfizer Vaccines: Behind the giant

Pfizer Vaccines business is one the biggest in the world, and plays host the best selling vaccine in the world: Prevnar 13. And despite a very small product list, Prevnar’s dominance over the pneumococcal market allows them to bring in over $4 billion ... [Published BioPortfolio - Jun 25 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Director – Prevenar 13 Adult Global Commercial Development &

Org Marketing StatementAll over the world, Pfizer colleagues are working together to positively impact health for everyone, everywhere. Each position at Pfizer touches and contributes to the success of our business and our world. That’s why, as one of ... [Published PharmaDiversity - Jun 24 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Top 10 Best-Selling Vaccines of 2013

#1. Prevnar family 15Prevnar 7/Prevenar 7: Pneumococcal 7-valent conjugate vaccine (diphtheria CRM 197 protein); Prevnar 13: Pneumococcal 13-valent conjugate vaccine (diphtheria CRM 197 protein)2013 sales: $3.974 billion2012 sales: $4.117 billion 16% ... [Published Genetic Engineering News - Jun 23 2014]

Quotes

...Those in the refrigerator recently cost $70,000, she said — "more than I paid for four years of medical school."
"Alright so listen I will give everybody a chance to answer a question when we get through and we'll be happy to answer any question from members of the media" Barbour said at first

More Content

All (72) | News (53) | Reports (0) | Blogs (19) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Roundtable: 3 Stocks Janet Yellen Is Dead Wrong... [Published Motley Fool Discussion Boards - Jul 19 2014]
Business Solutions Director, Business Analytics... [Published PharmaDiversity - Jul 18 2014]
Poverty, poor health, exposure are risk factors... [Published Orthopedics Today - Jul 16 2014]
Vaccine costs soar [Published Tampa Bay Times - Jul 16 2014]
Forum Post: RE: Vaccines and CLL [Published Macmillan Cancer Support - Jul 16 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 15 2014]
Prices of vaccines–an uncomfortable discussion [Published Daily Kos - Jul 15 2014]
Vanishing vaccinations [Published Register-Guard - Jul 14 2014]
Berko: Patience with drug firm Pfizer may event... [Published Columbian.com - Jul 13 2014]
Could soaring vaccine prices spark Sovaldi-styl... [Published FierceVaccines - Jul 11 2014]
GlycoVaxyn Trialing New Vaccine Technology For ... [Published BioPortfolio - Jul 09 2014]
Bexsero Vaccine: Searching for a villain [Published Sott.net - Jul 06 2014]
Briefly On Pfizer: It's Time To Buy [Published Seeking Alpha - Jul 03 2014]
Vaccine Refusal Myths Drive Up Development Cost... [Published Forbes.com - Jul 03 2014]
How Vaccines Got Really Expensive [Published Governing - Jul 03 2014]
Top 10 Vaccines in 2013 [Published Terrapinn - Jul 03 2014]
The big conversation starter: Vaccine prices [Published LifeHealthPro - Jul 03 2014]
Vaccines Cost an Absolute God-Almighty Fortune [Published Jezebel - Jul 03 2014]
Why do vaccines cost so much? Ask Pfizer about ... [Published FiercePharma - Jul 03 2014]
Vaccine Costs Rising, Some Doctors Stop Offerin... [Published Newser - Jul 03 2014]
Abbreviated Pundit Round-up: Here's to the stat... [Published Daily Kos - Jul 03 2014]
Prevnar use in seniors is cost-effective now, C... [Published FierceVaccines - Jun 30 2014]
Free vaccinations to protect babies against dea... [Published ONE News - Jun 30 2014]
The top 5 vaccines by 2020 [Published FierceVaccines - Jun 27 2014]
Global vaccine contract manufacturing market to... [Published Live-PR.com - Jun 26 2014]
CDC committee recommends AZ's FluMist over flu ... [Published FierceVaccines - Jun 26 2014]
Pfizer Vaccines: Behind the giant [Published BioPortfolio - Jun 25 2014]
Director – Prevenar 13 Adult Global Commercial ... [Published PharmaDiversity - Jun 24 2014]
Serotypes 15, 35B prevalent among PCV13-vaccina... [Published Orthopedics Today - Jun 23 2014]
Capital dearth hinders Nigerian Pharma firms fr... [Published Business Day Nigeria - Jun 23 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 15 2014]
Valeant's Misleading Case [Published In the Pipeline - Jun 12 2014]
Matthew Herper has excellent coverage here of Valeant's bid for Allergan, specifically Valeant's view of actual pharma R&D (which they, for the most part, don't bother to do). He's especially peeved (with reason) that the company is citing some of ...
Adult and Adolescent Vaccines Market to 2018 - ... [Published PR Newswire: Health - Jun 09 2014]
NEW YORK, June 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval ...
A Look at Pfizer’s Recent Financial Performance [Published Wall St. Cheat Sheet - May 15 2014]
Pfizer ( NYSE:PFE ) is getting a lot of attention lately, mostly given its potential deal with AstraZeneca ( NYSE:AZN ). This topic has been thoroughly covered lately. But despite the drama surrounding the headlines of late, Pfizer is still my ...
Where Will Pfizer Go Next? [Published Wall St. Cheat Sheet - May 06 2014]
With shares of Pfizer ( NYSE:PFE ) trading around $29, is PFE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : T = Trends for a Stock’s Movement Pfizer is a biopharmaceutical ...
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.